Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
154 stopped studies mapped to Ovarian Carcinoma and descendants · 90% state a reason
Over the 154 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04614051 | A Phase 1 Study of Cellgram-DC in Patients With Advanced or Recurrent Epithelial Ovarian… | Phase 1 | terminated | Nov 3, 2020 | Pharmicell Co., Ltd. | Difficulties in patient recruitment. | Enrollment / accrual |
| NCT04315233 | Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent…(CHARGE) | Phase 1 | terminated | Mar 19, 2020 | University of Utah | No accrual in one year | Enrollment / accrual |
| NCT06315491 | A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer | Phase 2 | terminated | Mar 18, 2024 | Cybrexa Therapeutics | Limited clinical activity | Other (stated, no rule matched) |
| NCT04840589 | Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid… | Phase 1 | suspended | Apr 12, 2021 | National Cancer Institute (NCI) | Other - Pending amendment. | Other (stated, no rule matched) |
| NCT03987555 | Paclitaxel Therapeutic Drug Monitoring in Cancer Patients | — | suspended | Jun 17, 2019 | Wake Forest University Health Sciences | Funding | Funding |
| NCT05226507 | A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in… | Phase 1 | terminated | Feb 7, 2022 | Nuvectis Pharma, Inc. | Study terminated due to various reasons impacting the feasibility of future clinical development | Other (stated, no rule matched) |
| NCT06666218 | Helping Ovarian Cancer Patients Cope With Their Illness (HOPE) | N/A | suspended | Oct 30, 2024 | Fred Hutchinson Cancer Center | Enrollment is currently paused. Aim 1 recruitment has finished, and the study team is preparing to… | Enrollment / accrual |
| NCT05451849 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | Phase 1 / Phase 2 | terminated | Jul 11, 2022 | TCR2 Therapeutics | No participants were enrolled in Phase 2 as Phase I was terminated early due to the lack of a clear… | Enrollment / accrual |
| NCT05991752 | Health-Economic Evaluation of Early Diagnosis of Epithalial Ovarian Cancer Recurrence…(ROMECO) | N/A | withdrawn | Aug 15, 2023 | University Hospital, Tours | feasibility issue | Other (stated, no rule matched) |
| NCT05523440 | Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer… | Phase 2 | terminated | Aug 31, 2022 | University of Oklahoma | Funding issue | Funding |
| NCT06630325 | A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced… | Phase 2 | terminated | Oct 8, 2024 | OHSU Knight Cancer Institute | Loss of support. | Other (stated, no rule matched) |
| NCT05397093 | ITIL-306 in Advanced Solid Tumors | Phase 1 | terminated | May 31, 2022 | Instil Bio | The study was terminated early due to discontinuation of development of the investigational program | Other (stated, no rule matched) |
| NCT06546553 | A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the… | Phase 1 | terminated | Aug 9, 2024 | Pfizer | Study terminated as part of strategic considerations and not based on safety concerns. | Safety / toxicity |
| NCT05756907 | Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant… | Phase 1 / Phase 2 | terminated | Mar 7, 2023 | Sonnet BioTherapeutics | Failed to meet efficacy endpoint criteria, despite lack of safety concerns | Safety / toxicity |
| NCT02364713 | MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian,… | Phase 2 | terminated | Feb 18, 2015 | Mayo Clinic | poor accrual | Enrollment / accrual |
| NCT04504916 | A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors… | Phase 2 | terminated | Aug 7, 2020 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Business reasons | Sponsor / business decision |
| NCT05194735 | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects… | Phase 1 / Phase 2 | terminated | Jan 18, 2022 | Alaunos Therapeutics | Funding | Funding |
| NCT05317078 | A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin… | Phase 1 | terminated | Apr 7, 2022 | Amgen | Sponsor strategic decision | Sponsor / business decision |
| NCT06264921 | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors | Phase 1 | terminated | Feb 20, 2024 | NiKang Therapeutics, Inc. | This study was terminated as a result of Sponsor portfolio reprioritization. | Sponsor / business decision |
| NCT05870748 | REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin… | Phase 2 / Phase 3 | terminated | May 23, 2023 | Sutro Biopharma, Inc. | Due to strategic business considerations, Sutro has deprioritized the development of luveltamab… | Safety / toxicity |
| NCT05200364 | A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in… | Phase 1 | terminated | Jan 20, 2022 | Sutro Biopharma, Inc. | Terminated Early | Other (stated, no rule matched) |
| NCT06285097 | A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced… | Phase 1 | terminated | Feb 29, 2024 | Pfizer | The trial was terminated for strategic business reasons; the decision was not based on any safety… | Safety / toxicity |
| NCT05092360 | Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With…(ARTISTRY-7) | Phase 3 | terminated | Oct 25, 2021 | Mural Oncology, Inc | Study terminated due to business and strategic decision. | Sponsor / business decision |
| NCT04159155 | A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer(CAN-STAMP) | Phase 2 / Phase 3 | terminated | Nov 12, 2019 | University Health Network, Toronto | Low accrual | Enrollment / accrual |
| NCT06299163 | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors | Phase 1 | terminated | Mar 7, 2024 | Numab Therapeutics AG | Business decision | Sponsor / business decision |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | Phase 2 | terminated | Oct 3, 2022 | Telix Pharmaceuticals (Innovations) Pty Ltd | Indication scouting for TLX250-CDx will continue in theranostic studies, with a therapeutic… | Other (stated, no rule matched) |
| NCT05274451 | A Study to Investigate LYL797 in Adults With Solid Tumors | Phase 1 | terminated | Mar 10, 2022 | Lyell Immunopharma, Inc. | Pipeline Reprioritization | Other (stated, no rule matched) |
| NCT05891197 | A Biomarker Screening Protocol for Participants With Solid Tumors(START) | — | terminated | Jun 6, 2023 | Lyell Immunopharma, Inc. | Pipeline Reprioritization | Other (stated, no rule matched) |
| NCT04019288 | AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent… | Phase 1 / Phase 2 | terminated | Jul 15, 2019 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT02419495 | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple… | Phase 1 | terminated | Apr 17, 2015 | M.D. Anderson Cancer Center | Administratively Complete | Other (stated, no rule matched) |
| NCT06393751 | Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment… | Phase 1 / Phase 2 | withdrawn | May 1, 2024 | National Cancer Institute (NCI) | Other - Protocol moved to Withdrawn | Other (stated, no rule matched) |
| NCT03277482 | Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer | Phase 1 | terminated | Sep 11, 2017 | Dana-Farber Cancer Institute | Expansion cohort was not open | Other (stated, no rule matched) |
| NCT03294694 | Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer | Phase 1 | terminated | Sep 27, 2017 | Dana-Farber Cancer Institute | Safety Implications | Safety / toxicity |
| NCT04442126 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Jun 22, 2020 | Numab Therapeutics AG | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
| NCT05672095 | Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant… | Phase 1 / Phase 2 | withdrawn | Jan 5, 2023 | City of Hope Medical Center | Abandoned | Other (stated, no rule matched) |
| NCT02756130 | Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade… | Phase 1 / Phase 2 | withdrawn | Apr 29, 2016 | Jonsson Comprehensive Cancer Center | funding was not secured | Funding |
| NCT03456700 | Auranofin and Sirolimus in Treating Participants With Ovarian Cancer | Phase 2 | terminated | Mar 7, 2018 | Mayo Clinic | The study is closed per results from the interim analysis. | Efficacy / futility |
| NCT02569957 | Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in… | Phase 2 | terminated | Oct 7, 2015 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | The trial was halted prematurely due to slow accrual. | Enrollment / accrual |
| NCT03610490 | Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or… | Phase 2 | terminated | Aug 1, 2018 | M.D. Anderson Cancer Center | Lack of Efficacy | Efficacy / futility |
| NCT02641639 | FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With… | Phase 2 / Phase 3 | terminated | Dec 29, 2015 | Mateon Therapeutics | The study was terminated early due to the lack of efficacy and the study sponsor's decision to no… | Efficacy / futility |
| NCT03164980 | QoL-Comparison Between Trabectedin/PLD and Pt-based Therapy in Patients With Pt-sensitive…(COMPASS) | Phase 4 | terminated | May 24, 2017 | North Eastern German Society of Gynaecological Oncology | A total of 204 patients were planned to be randomized. Due to slow recruitment of the trial, the… | Enrollment / accrual |
| NCT04889495 | A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in… | — | withdrawn | May 17, 2021 | Pfizer | The study was withdrawn due to global supply chain issue. Zirabev was not launching in Korea. | Drug supply |
| NCT04421547 | Efficacy of Letrozole in Recurrent Ovarian Cancer(MITO32) | Phase 3 | terminated | Jun 9, 2020 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Logistical problems impacting the speed of enrolment | Enrollment / accrual |
| NCT05714306 | PEP-DC and OC-DC Vaccine in High Grade Serous Ovarian Carcinoma(CHUV-OVACURE) | Phase 1 / Phase 2 | withdrawn | Feb 6, 2023 | Centre Hospitalier Universitaire Vaudois | Lack of funding | Funding |
| NCT04213794 | Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for…(TOASTIT) | Early Phase 1 | terminated | Dec 30, 2019 | Mayo Clinic | slow accrual | Enrollment / accrual |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor… | — | withdrawn | Aug 2, 2021 | Travera Inc | Abandoned prior to launch. | Other (stated, no rule matched) |
| NCT05261490 | Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With… | Phase 1 / Phase 2 | terminated | Mar 2, 2022 | Pfizer | A business decision was made by Pfizer to terminate and remove the Phase 2 expansion of this study… | Safety / toxicity |
| NCT04493619 | PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With… | Phase 1 / Phase 2 | terminated | Jul 30, 2020 | Opna Bio LLC | study terminated due to business realignment | Sponsor / business decision |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | Phase 2 | terminated | Aug 19, 2021 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
| NCT06068738 | Association of Ex Vivo Drug Response (EVDR) and Clinical Outcome in Ovarian Cancer(EXCYTE-1) | — | terminated | Oct 5, 2023 | Exscientia AI Limited | Study was terminated due to a strategic re-evaluation of the company's overall business and… | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 12 days agoSource updated Sep 18, 2026source: clinicaltrials